Oncopharmacology Unit

References 1. Taieb, J., Lapeyre-Prost, A., Laurent Puig, P. & Zaanan, A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br. J. Cancer 121, 434–42 (2019). 2. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010). 3. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R. et al.

Key message The Editorial Board of Annals of Oncology should be encouraged to moderate the race to a high IF. J.C. Soria, Editor in Chief of the journal, recently wrote an editorial which resounds like a hymn of praise to the impact factor []. Having remarkably reached the objective of raising the impact factor (IF) to 10, the Editor is now setting an even greater challenge by striving for an IF of 12 by 2018. As an author of numerous articles in the journal ever since its foundation, I feel …

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.